<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602221</url>
  </required_header>
  <id_info>
    <org_study_id>1289-0057</org_study_id>
    <nct_id>NCT04602221</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine</brief_title>
  <official_title>A Randomized, Placebo Controlled, Double-blind, Double-dummy Three-way Cross Over Trial to Investigate the Effect of BI 409306, BI 425809 and Lamotrigine on Ketamine-induced Cognitive Deficits in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809&#xD;
      and lamotrigine attenuate ketamine induced cognitive deficits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">April 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3-treatment period design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Paired Associate Learning (PAL) Total Errors Adjusted (PALTEA28) on ketamine</measure>
    <time_frame>up to 41 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spatial Working Memory (SWM) Between Errors (BE468) on ketamine</measure>
    <time_frame>up to 41 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid Visual Information Processing A' Prime (RVPA) on ketamine</measure>
    <time_frame>up to 41 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lamotrigine treatment (T1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 treatment (T2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment (R)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 treatment (T3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Lamotrigine treatment (T1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>BI 409306 treatment (T2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, Film-coated tablet</description>
    <arm_group_label>Placebo treatment (R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>BI 425809 treatment (T3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a physical examination, vital signs (BP, PR),&#xD;
             12-lead ECG, and clinical laboratory tests&#xD;
&#xD;
          2. Age of 18 to 55 years (inclusive)&#xD;
&#xD;
          3. BMI of 18.5 to 32 kg/m2 (inclusive)&#xD;
&#xD;
          4. Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with GCP and local legislation&#xD;
&#xD;
          5. Male subjects who meet any of the following criteria from at least 30 days before the&#xD;
             first administration of trial medication until 30 days after trial completion:&#xD;
&#xD;
               -  Use of adequate contraception, e.g. use of condom (male subjects) plus any of the&#xD;
                  following methods (female partners): intrauterine device, hormonal contraception&#xD;
                  (e.g. implants, injectables, combined oral or vaginal contraceptives) that&#xD;
                  started at least 2 months prior to first drug administration, or barrier method&#xD;
                  (e.g. diaphragm with spermicide)&#xD;
&#xD;
               -  Sexually abstinent&#xD;
&#xD;
               -  Vasectomised (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
               -  Surgically sterilised female partner (including hysterectomy, bilateral tubal&#xD;
                  occlusion or bilateral oophorectomy)&#xD;
&#xD;
               -  Postmenopausal female partner, defined as at least 1 year of spontaneous&#xD;
                  amenorrhea&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding in the medical examination (including ECG) deviating from normal and&#xD;
             assessed as clinically relevant by the investigator&#xD;
&#xD;
          2. Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 50 to 90 bpm&#xD;
&#xD;
          3. Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          4. Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)&#xD;
&#xD;
          7. History of diseases of the central nervous system (including but not limited to any&#xD;
             kind of seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further&#xD;
             exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling</last_name>
      <phone>+001(714)799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Hassman</last_name>
      <phone>+001(856)753-7335-x350</phone>
      <email>hhassman@hritrials.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>BI 425809</mesh_term>
    <mesh_term>BI 409306</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

